Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Multicenter Study on the Patterns and Clinical Significance of Lymph Node Metastasis in Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy Combined With Immunotherapy

NCT07899775 is registered in ClinicalTrials.gov with Hainan General Hospital as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07899775 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Multicenter Study on the Patterns and Clinical Significance of Lymph Node Metastasis in Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy Combined With Immunotherapy
Lead sponsor
Hainan General Hospital
Phase
Observational
Overall status
Not yet recruiting
Start date
January 1, 2027
Completion date
December 31, 2029
Enrollment
103 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

gastric adenocarcinoma, gastric cancer (diagnosis), stomach neoplasms

Arms

As registered; 1 arm.

  • Neoadjuvant Chemo-immunotherapy Cohort Neoadjuvant SOX chemotherapy combined with PD-1 inhibitor

    All enrolled participants receive standard neoadjuvant SOX chemotherapy combined with a PD-1 inhibitor for at least 2 cycles, followed by gastrectomy with D2 lymphadenectomy. No control group is assigned. Participants are observed prospectively from baseline through surgery and up to 3 years postoperatively.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Station-specific lymph node metastasis positivity rate after neoadjuvant chemoimmunotherapy Up to 2 weeks

    The primary outcome is the station-specific lymph node metastasis positivity rate after neoadjuvant chemoimmunotherapy, assessed by station-by-station pathologic examination of gastrectomy specimens. Each dissected nodal station (No. 1-No. 16, as applicable) is evaluated separately. For each station, the positivity rate is defined as the number of evaluable participants with at least one pathologically confirmed positive lymph node at that station divided by the number of evaluable participants in whom that station was pathologically assessed. A positive node is defined as a lymph node containing viable tumor cells on hematoxylin and eosin staining. Pathologic assessment is performed blinded to preoperative imaging, iRECIST response, and clinical treatment information. The outcome is assessed at postoperative pathology after D2 gastrectomy.

Similar trials

Same condition (Disease) and phase, most recent start first.